Introduction adenovirus-2 (Ad-2) and transfected with AAV Adeno-associated virus 2 (AAV), a nonpathogenic sequences. human parvovirus, causes latent infection of mammalian cells by integration into the host genome. 1 However, co-
Results
infection with adenovirus or herpes virus (helper viruses) is necessary to cause AAV to replicate, excise and proWith the background of successful replication of wildduce infectious viral particles. 2 The 145-bp inverted tertype AAV in vitro, 15, 16 we attempted to study the in vitro minal repeats (ITRs) are the sole cis-acting elements replication and eventual packaging of recombinant AAV responsible for rescue, replication and packaging of the sequences. We studied in vitro replication of DNA virus. [3] [4] [5] Transcripts from the p40 promoter produce viral sequences between AAV ITRs in the presence of required capsid protein while the p5 and p19 promoters code for essential elements that were provided through crude cell rep genes important in viral replication. 6 The AAV rep78 extracts. The same procedure was used to determine protein mediates AAV replication by its ATP-dependent whether or not the replicated sequences are packaged site-specific endonuclease and DNA helicase activity. 7 into AAV virions to determine its potential as a vector Peak production of both rep and capsid proteins in for gene transfer. human cells occurs between 12 and 24 h after infection. 8 The recombinant virus is produced by cotransfection of
In vitro AAV DNA replication a human cell line with (1) a recombinant plasmid containTo determine if recombinant AAV could be packaged in ing the gene of interest flanked by the 145-bp ITRs; (2) a vitro, we transfected adenovirus-2-infected HeLa cells plasmid containing all of the AAV sequences with modiwith a plasmid containing AAV sequences (pF or fications to prevent its packaging; and (3) adenovirus. 9, 10 pAAV/AD) encoding the viral structural and nonstrucIn vitro packaging of lambda DNA 11, 12 and in vitro reptural genes. Both pF and pAAV/AD have sequence lication and supercoiling of simian virus 40 DNA 13, 14 modifications to prevent them from being packaged. A have been well characterized. Recently, the in vitro replicrude cell extract was used to study replication and packcation of wild-type adeno-associated virus DNA, as aging as described in the Materials and methods. assayed by production of full-length excised AAV DNA Replication of the recombinant plasmid pLM10 conresistant to DpnI digestion was reported. 15, 16 However, in taining the LacZ gene between AAV ITRs was studied by vitro replication of recombinant virions and packaging of incubating the recombinant plasmid with the crude cell wild-type or recombinant AAV has not been demonlysate, nucleotide and deoxynucleotide triphosphates and strated previously. In the present study, we demonstrate other ions for 24 h. Subsequently, low molecular weight in vitro production of functional recombinant AAV from DNA was extracted by the described method and DNA was analyzed by Southern blot analysis. To confirm DNA replication, a DNA sample was digested with DpnI, which digests only methylated DNA; newly replicated CD16-specific primers. Various negative controls were utilized to confirm the specificity of packaging. The cell extract used for in vitro packaging must contain all AAV rep and cap proteins and for efficient production of each protein, cells must be transduced with plasmid containing AAV sequences (pF or pAAV/Ad), as well as with adenovirus. In the control samples where the cell lysate was prepared without pF or pAAV/Ad transfection or without adenovirus infection, no PCR bands are seen ( Figure 2, lanes 3 and 4) . Similarly, inactivation of the cell lysate before in vitro packaging results in no PCR amplification ( Figure 2 , lane 5). Production of recombinant AAV also requires a gene of interest between the AAV ITRs, so absence of AAV ITRs or linearization of the plasmid between AAV ITRs will not allow production of the recombinant AAV. As seen in Figure 2 , lanes 6 and 8, no PCR bands are observed; this suggests a failure to package. However, when all components of the system are present and intact, a 462-bp PCR fragment is amplified ( Figure 2 , lane 7), indicating successful packaging of recombinant virus. All of these requirements are similar to those needed for in vivo packaging of AAV.
Infectivity of in vitro packaged AAV Biological activity of the in vitro packaged virus was investigated by examining its infectivity of human cells. When HeLa cells are infected with different in vitro packaged extracts, the expression of Neo R gene can be studied by looking at development of resistance to the neomycin analogue G-418. In our study, only cells infected with extracts containing all the components, developed resistance to G418 at an active concentration of 800 g/ml. All A recombinant AAV containing LacZ gene was also packaged in vitro. HeLa cells were infected with in vitro packaged virus and control cells were infected with extracts with the LacZ gene inserted at a site other than between the AAV ITRs, making it unlikely to be packaged. As seen in Figure 4 , the presence of blue cells confirms transduction of HeLa cells while control extracts fail to transduce cells.
Prior transfection of the cells with wild-type AAV as a source of rep and cap products, or transfection of plasmidcontaining AAV sequences were equally effective in generating virus. In either case, a 24-h incubation period was required for virus generation (data not shown). Attempts to package AAV by first preparing the cell extract and then adding Ad-2, pF or pAAV/AD, and pMM-11 sim- ultaneously did not generate the virus; this suggests that the intact cell is needed for the initial expression of the viral structural and nonstructural genes.
Discussion
The results presented here describe successful in vitro production of a recombinant DNA virus using a lysed cell extract. In vitro packaging of lambda DNA has been described previously, in which an extract from a phageinfected E. coli supplies the mixture of proteins and precursors required for encapsidation of lambda DNA. 11, 12 Similarly, in vitro replication and supercoiling of simian virus 40 DNA have been well characterized. 13, 14 Soluble cell extracts from the nucleus and cytoplasm of human 293 cells have been shown to efficiently replicate a DNA template containing the origin of simian virus 40 replication. 17 The replication of wild-type AAV sequences have been described previously. 16 Using a plasmid-containing duplex form of AAV DNA in pBR322, replication of AAV sequences was demonstrated by production of full-length excised AAV DNA resistant to DpnI digestion excision of the AAV insert. 15, 16 Similarly, complex eukar-yotic DNA replication in a cell-free system has also been vitro produced rep and cap genes may obviate the need for plasmid transfection of the cells and adenoviral infecdescribed. 18 However, ours is the first report of in vitro replication and packaging of the recombinant virions.
tion. This also raises the possibility that we may be able to produce recombinant AAV without the need for adenThe in vitro replication and packaging of recombinant AAV described here conforms to all the characteristics of oviral infection, eliminating some safety and regulatory concerns. in vivo packaging such as presence of functional AAV rep and cap genes and packaging of genes only when they
The data presented here demonstrate the feasibility of AAV packaging in a cell-free system. This system should have been inserted between ITRs. 10 The in vitro packaged virus is detected by a PCR ampliallow further studies to evaluate the role of different cellular components in AAV packaging and the role of fication of a fragment of the gene, as the packaged DNA is protected from DNase I action. One unit of DNase I AAV-encoded proteins in the packaging of the virus. Because AAV is becoming an attractive vector for gene completely digests 1 g of plasmid DNA in 10 min at 37°C. We used DNase I at a very high concentration and transfer, [19] [20] [21] the availability of an in vitro packaging system promises to offer a safer packaging method, which for a prolonged period of time to digest the in vitro packaged extracts. Initially, they are digested with DNase I at in turn will help develop AAV as a vector for human gene therapy. 100 g/ml for 1 h and then 1000 g/ml for one additional hour to guarantee complete digestion of the unpackaged plasmid.
Materials and methods
A variety of negative controls was used for two reasons. First, the negative results so obtained confirm Cells and viruses the efficacy of the DNase I in destroying all unpackaged A nasopharyngeal carcinoma cell line, KB and HeLa cells plasmid, thus proving that the positive PCR reaction were cultured in RPMI supplemented with 10% fetal calf shows amplification of true DNA protected from DNase serum and 1% penicillin-streptomycin at 37°C in 5% CO 2 . I digestion. Second, these controls also demonstrate the Human adenovirus type 2 and wild-type AAV were various requirements for packaging of the AAV. Clearly kindly given by Dr A Srivastava, Indiana University the cell lysate prepared without adenovirus infection or School of Medicine, Indianapolis, IN, USA. without AAV sequences that produce rep and cap proteins is unable to package AAV. For in vivo packaging to Plasmids occur, the gene of interest must be between the ITRs. In Plasmid pAAV/Ad (a gift from Dr J Samulski, University our negative controls, the gene to be packaged was not of North Carolina, Chapel Hill, NC, USA) and pF (a gift between the ITRs or BglII endonuclease was used to from Dr P Hermonat, University of Arkansas for Medical digest pMM11 giving a linear DNA with the gene cleaved Sciences, Little Rock, AR, USA) have been previously between the AAV ITRs. We show that both these described. 9, 10 Plasmid pMM11 contains a SV-40 manipulations lead to failure of packaging in our system, promoter-driven human CD16 gene and thymidine kinas would be expected in in vivo packaging. An additional ase (TK) promoter driven neomycin resistance gene confirmation of the requirement for functional AAV probetween AAV ITRs. pMM4 contains the same construct teins in the lysate was shown by the inability to package without the AAV ITRs. The plasmid pLM10 contains the when previously heat-inactivated lysate was used.
LacZ gene driven by the phosphoglycerokinase (PGK) Although PCR is a very sensitive technique, able to detect promoter between AAV ITRs and plasmid pLM2 was the even a single copy of DNA, all of the negative controls same construct without AAV ITRs. with similar unpackaged plasmid contents provide further evidence that sequence amplification reliably Preparation of cell extracts interprets the packaging.
Cell extracts for in vitro packaging were produced from The titer obtained through this method has been HeLa cells infected with Ad-2 and co-transfected with extremely low suggesting that the in vitro packaging AAV/Ad or F using the calcium phosphate transfection described here may not be as efficient as in vivo packagmethod as described. 22 Twenty-four hours later, cells ing. Various possibilities can explain this finding. This were harvested by scraping. Following two washes with may be due to inefficient in vitro replication of the plas-PBS (pH 7.4), the cells are resuspended in PBS at a conmid, leading to decreased availability of replicative DNA centration of 2 × 10 7 cells/ml and subjected to three for packaging. Inadequate amounts and inadequate funcfreeze-thaw cycles (−80°C and 37°C). The cell lysates tioning of AAV rep and cap proteins may contribute to were cryopreserved at −80°C in smaller aliquots. The conthe inefficiency of the system. Additionally, the reaction trol lysate was prepared in the absence of specific compovolume in the in vitro system compared to the cell volume nents: without Ad-2 infection, without AAV/AD or F in vivo points to a dilution effect that may decrease the transfection. probability of packaging. Correction of the mechanisms possibly responsible for inefficient packaging will be important when broadly applying this method to proIn vitro replication and packaging The in vitro recombinant AAV replication was carried out duce recombinant AAV.
In vitro packaging provides a simple method for proin a 200-l reaction mixture containing 30 mm HEPES; 7 mm MgCl 2 ; 4 mm ATP; 4 g BSA (bovine serum duction of recombinant AAV without the need for expertise or extensive understanding of the biology of albumin); 200 m each of CTP, GTP and UTP; 100 m each of dATP, dGTP, dTTP and dCTP; 400 mm creatine AAV. It also decreases the packaging time from between 48 and 72 h to only 24 h. With the suggested modifiphosphate; 1 g creatine phosphokinase; and 150 l cell lysate. Then 10 g recombinant AAV plasmid pLM10 cations, better titers may be obtained for clinical application. It remains to be seen whether the addition of in was added. The reaction mixture was incubated for 24 h at 37°C and analyzed for DNA replication and virus cycles of incubation at 94°C (30 s), 61°C (30 s), and 72°C (45 s), followed by a 10-min extension period at 72°C. The packaging.
amplified fragments were separated by electrophoresis on 2% agarose gel and stained by ethidium bromide. Detection of DNA replication Low molecular weight DNA was extracted from the reac-
The second plasmid packaged in vitro was pLM10, containing the LacZ gene between AAV ITR or LM2 containtion mixture by Hirt extraction. 23 Briefly, a 100-l reaction mixture was mixed with 400 l Hirt solution at room ing the LacZ gene without AAV ITRs. The packaged products were digested by DNase I as described and HeLa temperature for 10 min; NaCl was added to a final concentration of 1.0 m, and kept at 4°C overnight. The procells were infected by the packaged products, and after 48 h, stained by X-gal to show virus-infected cells. ducts were then extracted with phenol:chloroform, precipitated by ethanol, and dissolved in 20 l water. Half of the sample was digested with DpnI for 2 h at 37°C.
